| Literature DB >> 22560151 |
Manuel Soto-Quiros1, Lydiana Avila, Thomas A E Platts-Mills, John F Hunt, Dean D Erdman, Holliday Carper, Deborah D Murphy, Silvia Odio, Hayley R James, James T Patrie, William Hunt, Ashli K O'Rourke, Michael D Davis, John W Steinke, Xiaoyan Lu, Joshua Kennedy, Peter W Heymann.
Abstract
BACKGROUND: The relevance of allergic sensitization, as judged by titers of serum IgE antibodies, to the risk of an asthma exacerbation caused by rhinovirus is unclear.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22560151 PMCID: PMC3792652 DOI: 10.1016/j.jaci.2012.03.040
Source DB: PubMed Journal: J Allergy Clin Immunol ISSN: 0091-6749 Impact factor: 10.793
Demographics and subjects' characteristics (February and October enrollments combined)
| Children with current wheeze (n = 96) | Children with stable asthma (n = 65) | Control subjects (n = 126) | |
|---|---|---|---|
| Mean age (y) | 8.8 | 9.1 | 9.4 |
| Sex (% male) | 58% | 58% | 47% |
| ED treatment for asthma, last 12 mo | 90% | 85% | NA |
| Hospitalization for asthma, last 12 mo | 10.5% | 15.4% | NA |
| Asthma medication use | |||
| Last 12 mo | 78% | 83% | NA |
| Last month | 60% | 51% | NA |
| Percent with daily use of: | |||
| Inhaled steroids | 36% | 54% | NA |
| Nasal steroids | 5%¶ | 26% | NA |
| Montelukast | 13% | 14% | NA |
| >10 d of school missed for asthma | 26% | 32% | NA |
| Worst season (% dry/rainy/not seasonal) | 4%/59%/37% | 2%/66%/33% | NA |
| Family history of asthma | |||
| Mother | 30%‖ | 31%§§ | 10% |
| Father | 17%‖ | 18%‡‡ | 4% |
| ETS exposure | 26%¶ | 11% | 27%‡‡ |
| ETS exposure from mother | 4% | 5% | 6% |
| ETS exposure from father | 13% | 3% | 18%†† |
NA, Not applicable.
Symbols marking significant differences between groups include the following: wheezing children versus nonasthmatic control subjects (‡P < .05, §P < .01, and ‖P < .001); wheezing children versus children with stable asthma (¶P < .05, #P < .01, and **P < .001); and children with stable asthma versus nonasthmatic control subjects (††P < .05, ‡‡P < .01, and §§P < .001). More details are shown in Table E1.
Percentage of parents reporting that their child's asthma was worse during the rainy or dry season or that their symptoms were not seasonal. Both wheezing children and those with stable asthma had symptoms that were worse during the rainy than the dry season (P < .001) or compared with children whose symptoms were not seasonal (P < .05).
For children with wheezing and those with stable asthma, the maternal history for asthma was significantly higher than the paternal history for asthma (P < .05).
Demographics and subjects' characteristics (February compared with October enrollments)
| Children with current wheeze | Children with stable asthma | Nonasthmatic control subjects | ||||
|---|---|---|---|---|---|---|
| February (n = 44) | October (n = 51) | February (n = 35) | October (n = 30) | February (n = 57) | October (n = 69) | |
| Mean age (y) | 8.7 | 9.0 | 9.3 | 8.8 | 9.8 | 9.1 |
| Sex (% male) | 57% | 59% | 54% | 63% | 39% | 54% |
| ED treatment for asthma, last 12 mo | 89% | 90% | 91% | 77% | NA | NA |
| Hospitalization for asthma, last 12 mo | 7% | 14% | 6% | 27%‡‡ | NA | NA |
| Asthma medication use | ||||||
| Last 12 mo | 82% | 74% | 86% | 80% | NA | NA |
| Last month | 43% | 74%§§ | 31% | 73%‖‖ | NA | NA |
| Percent with daily use of: | ||||||
| Inhaled steroids | 36%‖ | 35% | 66% | 40% | NA | NA |
| Nasal steroids | 4%‖ | 6%§ | 31% | 20% | NA | NA |
| Montelukast | 11% | 14% | 15% | 17% | NA | NA |
| >10 d of school missed for asthma | 18%§§ | 33% | 26% | 40% | NA | NA |
| Indoor dog/cat exposure | 9%*/23% | 6%/18% | 9%*/23% | 13%/20% | 25%/16% | 13%/22% |
| Worst season (% dry/rainy/not seasonal) | 7%/64%/29% | 2%/54%/44% | 5%/68%/26% | 0%/62%/38% | NA | NA |
| Family history of asthma: | ||||||
| Mother | 14%§§ | 43%‡ | 26%** | 37%** | 5% | 14% |
| Father | 20%† | 14% | 17%# | 20%# | 2% | 6% |
| ETS exposure | 20% | 31% | 11% | 10% | 28% | 26% |
| ETS exposure from mother | 2% | 6% | 6% | 3% | 9% | 9% |
| ETS exposure from father### | 7% | 18%§ | 3% | 3% | 21%# | 17%# |
NA, Not applicable.
Symbols marking significant differences between groups within each enrollment period include the following: wheezing children versus nonasthmatic control subjects (*P < .05, †P < .01, and ‡P < .001); wheezing children versus children with stable asthma (§P < .05, ‖P < .01, and ¶P < .001); and children with stable asthma versus nonasthmatic control subjects (#P < .05, **P < .01, and ††P < .001). Significant differences between the February and October enrollments for each group are indicated as follows: ‡‡P < .05, §§P < .01, and ‖‖P < .001.
Percentage of children requiring treatment in the ED or hospitalization for asthma during the last 12 months.
Percentage of children using medications (bronchodilator, controller, or both) for asthma during the timeframe indicated.
Percentage of children using inhaled corticosteroids, nasal steroids, or montelukast daily.
Percentage of children who missed more than 10 days of school for asthma during the previous year.
Percentage of children with dog or cat exposure in the home.
Percentage of parents reporting that their child's asthma was worse during the rainy or dry season or that their asthma symptoms were not seasonal. Both wheezing children and those with stable asthma enrolled in February and October experienced more asthma symptoms during the rainy compared with the dry season (P < .001).
Percentage of children exposed to at least 1 person at home who smoked 5 or more cigarettes a day.
Percentage of children whose mother or father smoked 5 or more cigarettes a day.
Percentage of children with positive test results for common respiratory tract pathogens by means of real-time PCR∗
| Children with current wheeze (n = 96) | Children with stable asthma (n = 64) | Control subjects (n = 126) | |
|---|---|---|---|
| Any virus | 83% (80)§ | 17% (11) | 21% (27) |
| Rhinovirus, all groups | 64% (61)§ | 13% (8) | 13% (17) |
| Group C | 75% (46)§ | 50% (4) | 35% (6) |
| Group A | 25% (15)‡ | 25% (2) | 47% (8) |
| Group B | 1% (1) | 25% (2) | 18% (3) |
| RSV | 10.4% (10)‡ | 0% (0) | 1% (1) |
| Metapneumovirus | 2.0% (2) | 3.1% (2) | 1% (1) |
| Parainfluenza virus (1, 2, and 3) | 2.0% (2) | 0% (0) | 0% (0) |
| Adenovirus | 2.0% (2) | 0% (0) | 1.6% (2) |
| Coronavirus | 2.0% (2) | 1.6% (1) | 4.0% (5) |
| Influenza A and B | 2.0% (2) | 0% (0) | 1% (1) |
| Enterovirus | 6.3% (6)† | 1.6% (1) | 1% (1) |
The percentage of children with positive test results for each virus is shown in the table, followed by the number of children with positive test results in parentheses. Significant differences between wheezing versus nonwheezing children (children with stable asthma and nonasthmatic subjects combined) are indicated as follows: †P < .05, ‡P < .01, and §P < .001.
This subject had positive test results for both group A and B strains.
Percentage of children with positive test results for rhinovirus with positive test results for group C, A, or B strains.
Results for coronavirus include positive test results for 229E, NL63, OC43, and HKU1 species.
One wheezing subject and 1 nonasthmatic control subject enrolled in October had a positive test result for 2009 H1N1. One wheezing subject had a positive test result for influenza B and for RSV.
Six of the 8 positive test results for enterovirus were positive for strain 68, which was previously reported to induce attacks of asthma in children.
Fig 1Percentage of children with positive test results by using real-time PCR for rhinovirus (RV; blue columns), enterovirus (HEV; orange columns), or RSV (yellow columns), each of which was significantly associated with wheezing, as noted in Table III. Data are shown for children enrolled in February during the dry season and October during the rainy season. Of the 3 viruses, only rhinovirus was present in nasal secretions from subjects in February. P = .029 for the comparison of positive test results for rhinovirus (80% [35/44]) in February versus October (48% [25/51]).
Assessments of allergen-specific IgE antibody levels (February and October enrollments combined)
| Children with current wheeze (n = 95) | Children with stable asthma (n = 65) | Control subjects (n = 123) | ||||
|---|---|---|---|---|---|---|
| % Positive | IgE antibody titers | % Positive | IgE antibody titers | % Positive | IgE antibody titers | |
| IgE antibody (IU/mL) to: | ||||||
| Any allergen | 96‡§ | NA | 84†† | NA | 54 | NA |
| Dust mite | ||||||
| | 90‡ | 25 (16-39)‡§ | 78†† | 11 (6-18)†† | 40 | 1.2 (0.8-1.8) |
| | 93‡§ | 18 (12-27)‡§ | 78†† | 8 (5-12)†† | 39 | 1.1 (0.8-1.5) |
| | 90‡ | 12 (8-18)‡ | 81†† | 8 (5-12)†† | 40 | 1.0 (0.7-1.4) |
| Other allergens | ||||||
| | 53‡ | 1.8 | 41** | 3.2# | 24 | 1.6 |
| | 38‡ | 1.4 | 33†† | 1.7 | 11 | 1.3 |
| | 42‡ | 0.7 | 36** | 0.7 | 18 | 0.4 |
| | 4* | 2.4 | 3 | ND | 0 | ND |
| | 12† | 0.9 | 10# | 0.6 | 2 | 1.2 |
| Dog dander | 25‡ | 1.3 | 18** | 1.1 | 6 | 1.3 |
| Cat dander | 16 | 1.8 | 15 | 2.9 | 8 | 2.1 |
| Bahia grass | 11 | 1.4 | 13 | 4.8 | 7 | 1.7 |
NA, Not applicable; ND, not determined.
Symbols marking significant differences between groups include the following: children with wheezing versus nonasthmatic control subjects (*P < .05, †P < .01, and ‡P < .001); children with wheezing versus those with stable asthma (§P < .05, P < .01, and P < .001); and children with stable asthma versus nonasthmatic control subjects (#P < .05, **P < .01, and ††P < .001).
Percentage of children with IgE antibody levels of 0.35 IU/mL or greater to each allergen.
IgE antibody titers are shown as GMs. GMs are followed by 95% CIs in parentheses for the dust mite species. GMs for other allergens include only children whose allergen-specific IgE levels were 0.35 IU/mL or greater.
Gene sequencing identification of rhinovirus strains according to group (A, B, or C)
| Group A | Group C | Group B | ||||
|---|---|---|---|---|---|---|
| Strain | Positive test results per strain | Strain | Positive test results per strain | Strain | Positive test results per strain | |
| Children with current wheeze | RVA(7) | 2 | RVC | 46 | RVB(86) | 1 |
| RVA(24) | 1 | |||||
| RVA(33) | 1 | |||||
| RVA(44) | 3 | |||||
| RVA(46) | 1 | |||||
| RVA(58) | 1 | |||||
| RVA(68) | 1 | |||||
| RVA(94) | 1 | |||||
| RVA(98) | 2 | |||||
| Children with stable asthma | RVA(1B) | 1 | RVC | 4 | RVB(48) | 1 |
| RVA(NT) | 1 | RVB(86) | 1 | |||
| Control subjects | RVA(36) | 1 | RVC | 7 | RVB(83) | 1 |
| RVA(39) | 2 | RVB(86) | 2 | |||
| RVA(46) | 1 | |||||
| RVA(82) | 2 | |||||
| RVA(89) | 1 | |||||
| RVA(NT) | 1 | |||||
NT, New type.
Coinfection with RVA(98) and RVB(86).
Assessments of total IgE, allergen-specific IgE antibody, and Feno levels (February compared with October enrollments)
| Children with current wheeze (n = 95) | Children with stable asthma (n = 65) | Control subjects (n = 123) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| February (n = 43) | October (n = 52) | February (n = 35) | October (n = 30) | February (n = 57) | October (n = 66) | |||||||
| % Positive | IgE antibody titers | % Positive | IgE antibody titers | % Positive | IgE antibody titers | % Positive | IgE antibody titers | % Positive | IgE antibody titers | % Positive | IgE antibody titers | |
| Total serum IgE (IU/mL) | 456 (332-627)‡ | 504 (377-673)‡ | 328 (164-657)** | 374 (206-681)†† | 111 (76-162) | 86 (59-127) | ||||||
| F | 41 (32-53)‡§ | 30 (24-37)‡ | 27 (21-36)‡ | 23 (17-32)* | 13 (10-16) | 15 (13-19) | ||||||
| IgE antibody (IU/mL) to: | ||||||||||||
| Any allergen | 93‡ | NA | 98‡ | NA | 79** | NA | 90†† | NA | 49 | NA | 58 | NA |
| | 86‡ | 21 (11-41)‡ | 92‡ | 29 (16-53)‡ | 74†† | 8 (4-17)†† | 83†† | 15 (7-34)†† | 35 | 1.2 (0.7-2.2) | 44 | 1.2 (0.7-2.1) |
| | 88‡ | 18 (10-32)‡§ | 96‡ | 19 (11-32)‡ | 74†† | 6 (3-12)†† | 83†† | 10 (5-20)†† | 37 | 1.1 (0.6-1.8) | 41 | 1.1 (0.7-1.7) |
| | 91‡ | 12 (7-22)‡ | 90‡ | 12 (7-21)‡ | 74** | 6 (3-11)†† | 90†† | 10 (5-20)†† | 40 | 0.9 (0.5-1.5) | 39 | 1.1 (0.7-1.8) |
| | 48† | 1.6 | 58‡ | 2.0 | 41 | 2.5 | 40 | 4.2# | 23 | 1.9 | 24 | 1.4 |
| | 36* | 1.2 | 38‡ | 1.6 | 32# | 1.3 | 33** | 2.3 | 14 | 1.2 | 9 | 1.4 |
| | 51‡ | 1.6 | 35 | 2.0 | 30** | 2.1 | 43# | 2.1 | 18 | 1.0 | 18 | 1.0 |
| | 0 | NA | 8† | 2.4 | 3 | NA | 4 | NA | 0 | NA | 0 | NA |
| | 7 | 0.7 | 16† | 0.9 | 12 | 0.8 | 7 | 0.5 | 4 | 0.8 | 2 | 2.6 |
| Dog dander | 17 | 1.1 | 31‡ | 1.4 | 9 | 1.1 | 26** | 1.1 | 9 | 1.0 | 3 | 2.0 |
| Cat dander | 12 | 1.3 | 20* | 2.1 | 12 | 2.1 | 18 | 3.9 | 10 | 1.8 | 6 | 2.6 |
| Bahia grass | 7 | 1.9 | 14 | 1.2 | 12 | 13.5 | 14 | 1.7 | 7 | 1.0 | 6 | 2.9 |
NA, Not applicable.
Symbols marking significant differences between groups within the same enrollment period (February or October) include the following: wheezing children versus nonasthmatic control subjects (*P < .05, †P < .01, and ‡P < .001); wheezing children versus children with stable asthma (§P < .05, ‖P < .01, and ¶P < .001); and children with stable asthma versus nonasthmatic control subjects (#P < .05, **P < .01, and ††P < .001).
GMs for total serum IgE and Feno levels are followed by 95% CIs in parentheses.
Percentage of children with IgE antibody levels of 0.35 IU/mL or greater to each allergen.
IgE antibody titers are shown as GMs. GMs for the dust mite species are followed by 95% CIs in parentheses. GMs for other allergens include only children whose allergen-specific IgE levels were 0.35 IU/mL or greater.
Odds ratio for wheezing based on positive test results for rhinovirus and titers of IgE antibodies (in international units per milliliter) to dust mite (D pteronyssinus)
| Titer of IgE antibodies to mite: | <0.35 IU/mL | 0.35-17.4 IU/mL | ≥17.5 IU/mL | ||||
|---|---|---|---|---|---|---|---|
| No. | PCR negative | PCR positive (A/C) | PCR negative | PCR positive (A/C) | PCR negative | PCR positive (A/C) | |
| Wheezing children | 95 | 5 | 4 | 8 | 16 (3/10) | 20 | 42 (8/30) |
| Nonwheezing children | 186 | 73 | 15 (6/5) | 43 | 7 (2/3) | 45 | 3 (1/2) |
| Stable asthma | 63 | 13 | 2 (0/1) | 12 | 5 (1/2) | 31 | 1 (0/1) |
| Control | 123 | 60 | 13 (6/4) | 31 | 2 (1/1) | 14 | 2 (1/1) |
| Odds ratio | 3.89 (0.9-16), | 12.3 (3.8-39), | 31.5 (8.3-108), | ||||
The number in parentheses indicates the number of subjects with positive test results for group A and group C strains of rhinovirus.
Two of these 4 children had IgE antibody to B tropicalis: 24.3 and 1.66 IU/mL.
Children with stable asthma combined with nonasthmatic control subjects.
Odds ratio for wheezing among rhinovirus-positive (real-time PCR) compared with rhinovirus-negative subjects.
Fig 2Probability of current wheezing based on increasing titers of IgE antibodies to D pteronyssinus in children with negative test results for rhinovirus by using real-time PCR (A) compared with children with positive test results for rhinovirus (B).
IgE antibody and group of subjects testing positive for enterovirus or RSV
| Virus | Group | Specific IgE antibody titers | Total IgE | F | |||||
|---|---|---|---|---|---|---|---|---|---|
| Cat dander | |||||||||
| Enterovirus | Current wheeze | <0.35 | <0.35 | <0.35 | 591 | 12 | |||
| Current wheeze | <0.35 | <0.35 | <0.35 | <0.35 | 100 | 31 | |||
| Stable asthma | <0.35 | <0.35 | 273 | 26 | |||||
| Current wheeze | <0.35 | 4712 | 14 | ||||||
| Current wheeze | <0.35 | <0.35 | 769 | 24 | |||||
| Current wheeze | <0.35 | <0.35 | 1365 | 62 | |||||
| Current wheeze | <0.35 | <0.35 | <0.35 | 181 | 22 | ||||
| RSV | Control | <0.35 | <0.35 | 119 | 31 | ||||
| Current wheeze | <0.35 | <0.35 | <0.35 | <0.35 | 144 | 5 | |||
| Current wheeze | <0.35 | <0.35 | 414 | 29 | |||||
| Current wheeze | <0.35 | <0.35 | 890 | 14 | |||||
| Current wheeze | <0.35 | 543 | 48 | ||||||
| Current wheeze | <0.35 | <0.35 | <0.35 | <0.35 | <0.35 | 55 | 19 | ||
| Current wheeze | <0.35 | <0.35 | <0.35 | 460 | 11 | ||||
| Current wheeze | <0.35 | <0.35 | 476 | 29 | |||||
| Current wheeze | <0.35 | 11.0 | <0.35 | <0.35 | 102 | 20 | |||
| Current wheeze | <0.35 | <0.35 | <0.35 | 638 | 6 | ||||
Titers of specific and total serum IgE antibodies are in international units per milliliter. Specific IgE antibody titers in boldface are considered positive, and those in italics are considered high titer (≥17.5 IU/mL).
One control subject did not have serum IgE data but had positive results for enterovirus by using real-time PCR on nasal secretions.
This subject with current wheeze was coinfected with enterovirus and RSV.
This subject with current wheeze was coinfected with RSV and human rhinovirus group C.
Fig 3Relationship between measurements of Feno levels (in parts per billion) and increasing titers of IgE antibodies to D pteronyssinus. Results are shown for children with titers of IgE antibodies of 0.35 IU/mL or less, 0.35 to 17.4 IU/mL, and 17.5 IU/mL or greater. GM values for Feno for each group are shown in red.